Spartalizumab Biosimilar, Human PD-1 Monoclonal Antibody
Spezifität
The in vivo grade spartalizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1), antagonizing its interaction with its known ligands PD-L1 and PD-L2.
Produktmerkmale
Recombinant Humanized IgG4 Monoclonal Antibody.
Aufreinigung
Protein A affinity column
Reinheit
> 95% by SDS-PAGE under reducing conditions and HPLC.
Sterilität
0.2 μm filtered
Endotoxin-Niveau
< 1 EU per 1 mg of the protein by the LAL method.
Immunogen
The anti-human PD-1 monoclonal antibody spartalizumab biosimilar was produced in mammalian cells.
Isotyp
IgG4 kappa
Applikationshinweise
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by spartalizumab.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
PBS, pH 7.4, no stabilizers or preservatives.
Konservierungsmittel
Without preservative
Handhabung
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Haltbarkeit
12 months
Target
PDCD1 (Spartalizumab Biosimilar)
Substanzklasse
Biosimilar
Hintergrund
Spartalizumab Biosimilar uses the same protein sequences as the therapeutic antibody spartalizumab. A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.